177 results about "Cell damage" patented technology

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an iNOS inhibitor in preparation of a medicine for relieving cellular injury caused by toxin combined exposure. KK-1 cells serve as a research model, it is shown for the first time that MC-LR and NaNOS combined contamination can remarkably up-regulate the expression level of iNOS protein, and it is found through tests that Nos2 gene silencing can remarkably relieve tight junction damage and cell apoptosis caused by toxin combined exposure in the KK-1 cells; it is revealed for the first time that iNOS is a core target of toxin combined exposure induced cell tight junction damage and apoptosis, and the blank of toxic mechanism research in toxin combined exposure is filled. The application provides a new direction for a detoxification strategy of environmental toxin combined exposure, provides a theoretical basis for developing an iNOS-targeted inhibitor, and also provides a new target for etiological recognition, early diagnosis and prevention of related diseases caused by environmental toxin combined exposure.

The invention provides a specific sequence nucleic acid molecule and application thereof as a PDRN, and relates to the technical field of biology. A novel nucleic acid molecule with a specific sequence is obtained, and the sequence has certainty, biological activity and stable product quality. The PDRN of the specific sequence does not have cytotoxicity, is high in safety and has a wide application prospect. Moreover, compared with the extracted PDRN, the PDRN with a specific sequence is found for the first time, the product has a remarkable effect of promoting VEGF expression, cell damage can be effectively repaired, and a novel skin-care and repairing functional component is provided for the industries of cosmetics and medicines. The invention further provides a preparation method of the PDRN with the specific sequence, and the preparation method is simple and suitable for popularization, application and industrial production.

The invention relates to the technical field of biological medicines, in particular to application of an EIF3A inhibitor in preparation of a medicine for treating hepatic fibrosis. The EIF3A inhibitor relieves the hepatic fibrosis process by inhibiting EIF3A expression of hepatic tissue, relieving endoplasmic reticulum stress, inhibiting an NF-kappa B inflammation pathway and reducing pathological damage of hepatic cells, and the EIF3A inhibitor can be selected from a medicine for knocking down or knocking out EIF3A, a medicine for inhibiting EIF3A protein synthesis or a medicine for promoting EIF3A protein degradation. New mechanism research is provided for occurrence and development of hepatic fibrosis, hepatic cell damage and inflammation can be relieved through targeting EIF3A, hepatic fibrosis related pathological phenotypes are relieved, the protection and treatment effects are achieved, safety is higher, and therefore the application has good practical application value.

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

The application belongs to the technical field of biology, and particularly relates to an antibacterial polypeptide LAB-129 and application thereof. The application is based on an antibacterial peptide LAB-4 with antibacterial activity from a Shanxi old vinegar source, adopts a random fragmentation strategy to split the complete sequence into multiple short peptide fragments with 5-50 amino acid residues, and screens a new antibacterial peptide LAB-129 with higher antibacterial activity. Compared with the LAB-4, the LAB-129 has stronger antibacterial activity, lower MIC, higher membrane damage capacity and cell damage effect, and exhibits better overall antibacterial effect, thereby laying a good foundation for developing a new microbial proliferation inhibitor to replace traditional antibiotics.

The invention provides a single cell damage detection method and device, computing equipment and a readable storage medium, and belongs to the technical field of microbiological detection. The method comprises the following steps: collecting single-cell Raman spectrum data of microorganisms; performing quality control processing on the single cell Raman spectrum data, and determining a Raman intensity value of the single cell in a predetermined Raman shift interval; inputting the Raman intensity value of the single cell in the preset Raman shift interval into a trained neural network model, and determining a reconstruction error value of the single cell; and determining whether the microbial single cell is damaged based on the difference between the reconstruction error value of the single cell and a reference reconstruction error value. The method has the advantages of non-invasiveness, real-time detection, high sensitivity, high safety, rich information amount, simplicity and convenience in operation and the like in single cell damage detection.

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

A YL1-tiRNA for promoting mouse muscle cell injury repair belongs to the technical field of molecular biology, the YL1-tiRNA is formed by cutting mature mt-Tv, a phosphate group is added at the 5th terminal, phosphorylation modification is carried out on the sequence, and a section of sequence is added at the 5th terminal without changing the function of the sequence, the YL1-tiRNA is characterized in that the nucleotide sequence of the YL1-tiRNA is shown as Seq ID No: 1, and the nucleotide sequence of the YL1-tiRNA is shown as Seq ID No: 1. Experiments prove that the YL1-tiRNA can promote mouse muscle injury repair by regulating proliferation of C2C12 cells.

The invention relates to the technical field of food processing, in particular to a freeze-dried broccoli processing method. The invention provides a freeze-dried broccoli processing method which comprises the following steps: taking cleaned broccoli, and cutting the broccoli into small flower types which are consistent in size, shape, thickness and height; carrying out instantaneous fixation by adopting steam, immediately soaking the broccoli subjected to fixation in ice water, fishing out the broccoli, and draining water; stacking the quick-frozen broccoli and the dry ice layer by layer; and after the temperature of the broccoli is reduced to-40 DEG C to-60 DEG C, performing vacuum freeze drying until the water content is less than or equal to 3% to obtain the dehydrated broccoli. According to the method, the loss of functional components such as glucoraphanin and polyphenol is reduced; formation of ice crystals is reduced, cell damage is reduced to the maximum extent, the content of functional components is effectively maintained, the color is close to that of fresh broccoli, and rehydration performance is good; the retention rates of functional components of glucoraphanin, flavone and vitamin C in broccoli all reach 98% or above.

This invention provides specific sequence nucleic acid molecules and their applications as PDRNs, relating to the field of biotechnology. This invention yields novel specific sequence nucleic acid molecules with deterministic sequences, stable biological activity, and stable product quality. The PDRNs with these specific sequences are non-cytotoxic, exhibit high safety, and have broad application prospects. Furthermore, this invention is the first to discover that specific sequence PDRNs, compared to extracted PDRNs, significantly promote VEGF expression and effectively repair cell damage, providing a novel skincare and repair ingredient for the cosmetics and pharmaceutical industries. This invention also provides a simple method for preparing specific sequence PDRNs, suitable for widespread application and industrial production.

The present invention addresses the problem of providing a novel treatment method for T-cell tumors that can induce cell damage in tumor cells and can be used in the treatment of a T-cell tumor of a subject with T-cell dysfunction. The present invention provides a therapeutic agent for a T-cell tumor of a subject with T-cell dysfunction, said therapeutic agent comprising a bispecific antigen-binding molecule, wherein the bispecific antigen-binding molecule includes (1) at least one section that specifically binds to a target tumor antigen expressed in T-cell tumor cells, and (2) at least one section that specifically binds to an antigen which is a normal T-cell-side target antigen and has a subtype, provided that the target tumor antigen expressed in T-cell tumor cells is not present in normal T-cells, or if present, the normal T-cells are substantially not activated when the bispecific antigen-binding molecule binds to the antigen that is present in the normal T-cells and is the same as the target tumor antigen, and a sufficient ratio of the subtype of the normal T-cell-side target antigen is present such that the normal T-cells are activated by the bispecific antigen-binding molecule binding to the normal T-cell-side target antigen and a sufficient number of activated T-cells for treatment of the T-cell tumor are provided.

The invention relates to the technical field of neutrophile granulocyte separation, in particular to a mouse neutrophile granulocyte separation method which comprises the following steps: (1) anesthetizing and disinfecting a mouse; (2) tissue sampling; (3) tissue digestion; (4) preparing a cell suspension; (5) purifying cells; (6) cell culture; according to the method disclosed by the invention, isoflurane is adopted in the anesthesia disinfection step, so that central nervous activity of mice can be rapidly inhibited, tissue damage caused by stress reaction is avoided, and chemical stimulation can be reduced while body surface microorganisms are cleared through combination of ethanol disinfection and sterile normal saline flushing, and aortic tissues with intact activity are provided for subsequent material taking. In the compound enzyme digestive juice, collagenase I can specifically degrade aortic wall collagenous fibers, trypsin dissociates adhesion connection between cells, neutral protease assists in decomposing elastic fibers, and DNA enzyme I is supplemented to inhibit cell aggregation, so that the contradiction between incomplete digestion and large cell damage of the traditional enzyme juice is effectively solved.

The invention discloses an application of a vinyl quinoline fluorescent dye in preparation of a reagent or a kit for detecting mitochondria or lysosome. The fluorescent dye does not need to be washed, the probe is used for dyeing mitochondria when the mitochondrial membrane potential is normal, and the probe targets lysosome when the mitochondrial membrane potential is reduced, so that the probe can also be used for observing the mitochondrial membrane potential, the influence of washing on the mitochondrial membrane potential and the damage to cells can be avoided, and the applicability is wider.

The invention relates to the technical field of aluminum electrolysis, and provides an aluminum electrolysis cell damage inversion method based on a machine learning algorithm, and the method comprises the following steps: obtaining the current data of an aluminum electrolysis cell through an optical fiber current sensor, and obtaining the temperature data of the aluminum electrolysis cell; carrying out blanking area division according to a blanking device of the aluminum electrolysis cell; performing regional division on the current data and the temperature data, and performing feature extraction on the current data and the temperature data; establishing a physical information forward model based on a neural network, and performing association mapping on the damage state vector, the current characteristic data and the temperature characteristic data through the physical information forward model; constructing a cathode joint loss function and an anode joint loss function; and respectively carrying out iterative solution on the cathode joint loss function and the anode joint loss function through an optimization algorithm, outputting an optimal damage state vector, and generating a damage space distribution result of the electrolytic cell. According to the invention, online inversion and spatial distribution visualization of the damage states of the anode and the cathode can be realized.

The invention discloses gamma-aminobutyric acid and application of a pharmaceutical composition thereof in preparation of drugs for preventing or treating aortic dissection and aortic aneurysm. The invention provides the application of gamma-aminobutyric acid in preparation of drugs for preventing or treating aortic dissection for the first time, and verifies the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting endothelial cell dysfunction; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting expression of c-FOS to reduce vascular endothelial cell injury is verified; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by reducing infiltration of macrophages is verified.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis. Using human neuroblastoma cells (SH-SY5Y) as target cells, this invention utilizes activators from a library of ubiquitinated compounds to target and activate key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This helps to understand the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention experimentally discovered that NEDD8 activator (NAE) has the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis, offering new targets and treatment strategies for the prevention and treatment of JEV.

The application discloses application of a miR-8069 inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-8069 in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-8069 can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a model of cerebral stroke in vitro in research. The miR-8069 inhibitor disclosed by the application is used for preparing a medicine for treating cerebral stroke, and the nucleotide sequence is as follows: ACCGCCGACCGCCCCCAACCAUCC.

The application relates to the field of nanobiomedical technology, and particularly relates to application of polyethylene glycol modified black phosphorus nanosheets in prevention and treatment of acute liver injury. The polyethylene glycol modified black phosphorus nanosheets not only have a significant active oxygen scavenging capacity, but also have calcium ion chelation and buffering capacity, can simultaneously regulate intracellular oxidation-reduction homeostasis and calcium homeostasis, inhibit intracellular calcium overload, especially mitochondrial calcium overload, maintain mitochondrial function, and further reduce liver cell damage, apoptosis and inflammatory response, and play a liver protection role. The application finds that the black phosphorus nanosheets are used in calcium ion chelation and inhibition of cell calcium overload, and breaks through the limitation that the black phosphorus nanosheets are mainly used as active oxygen scavenging materials in the prior art. The material can also adsorb copper ions and realize radioactivity copper labeling without chelating agent, and can be used for liver enrichment tracing and integrated diagnosis and treatment application. The material has a significant protective effect on paracetamol-induced acute liver injury.

The invention discloses a composite medicine coating for treating pulmonary arterial hypertension, and belongs to the technical field of medical instruments. The coating is composed of an inert protective layer and a composite drug coating, the inert protective layer is a polyamino acid polymer, responds to pH change and is rapidly disintegrated only in the pH environment of a target site, and the loss of the composite drug coating in the delivery process is reduced; the composite drug coating is a composite component containing two or more gene regulatory factors and / or drugs, achieves a synergistic effect through a signal path, cells and a gene level, more efficiently regulates pulmonary artery endothelial cell dysfunction and smooth muscle cell injury, and has precise targeting and irreplaceability.

The present application belongs to the technical field of application of fungal polysaccharides, and particularly relates to a Boletus edulis fruiting body polysaccharide as well as a preparation method and application thereof. Polysaccharides in Boletus edulis fruiting bodies are extracted, and the chemical structure of BDP-F is characterized by ultraviolet-visible light, Fourier transform infrared spectroscopy, one-dimensional nuclear magnetic resonance and two-dimensional nuclear magnetic resonance. The research results show that BDP-F is mainly composed of mannose, glucose, galactose and fucose. Methylation and nuclear magnetic resonance analysis show that the glycosidic bond of BDP-F is (1→6)-alpha-d-galactose, the main chain is composed of ->6)-alpha-d-galp-(1→ residues, and the O-2 position is branched by alpha-L-Fucp-(1→ and alpha-D-Manp-(1→ residues. Through DPPH free radical, hydroxyl radical and superoxide anion radical scavenging experiments, it is shown that BDP-F has the ability to serve as a natural antioxidant, and BDP-F can also reduce alcohol-induced GES-1 cell damage through antioxidant and anti-inflammatory effects within the experimental concentration range.

Systems and methods of the present disclosure provide a service loop for a pouch cell tab by bending the service loop into the cord length at the cell-level. Embodiments of the present disclosure reduces the risk of cell damage or open circuit welds. Both failure modes have the potential to open circuit a battery mid-operation or trigger a thermal runaway. According to various embodiments, the service loop is integral to the pouch such that no additional parts are used to form the pouch cell.

The application discloses an application of a miR-4680-3p inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-4680-3p in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-4680-3p can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a classic model of cerebral apoplexy in vitro in research. The miR-4680-3p inhibitor disclosed by the application is used for preparing a medicine for treating ischemic apoplexy, and the nucleotide sequence of the miR-4680-3p inhibitor is as follows: UAACAACUCUUACAAUUCAGA.

The invention relates to the technical field of biomedical detection, and discloses an umbilical cord blood unfreezing reference specimen cell counting and flow cytometry dilution method which comprises the following steps: S1, preparing an unfreezing solution which is composed of HES, AB plasma and PBS, and placing the unfreezing solution at room temperature for later use; s2, taking the unfrozen umbilical cord blood unfreezing reference specimen, adding an unfreezing solution into the umbilical cord blood, firstly gently and uniformly mixing, then standing at room temperature, then continuing to add the unfreezing solution, gently and uniformly mixing again, then standing at room temperature, and stabilizing; s3, taking the diluted umbilical cord blood, and carrying out cell counting by adopting a counting instrument; and S4, taking the diluted umbilical cord blood again, and dyeing. The unfreezing solution composed of HES, AB plasma and PBS synergistically regulates osmotic pressure, provides cell nutrition, stabilizes the pH value, reduces the damage of the cryoprotectant to cord blood cells, maintains the cell activity, and improves the problem of result deviation caused by direct detection of cell damage in the prior art.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator enzyme inhibitors or their hydrochlorides in the preparation of drugs for treating Japanese encephalitis. This invention utilizes inhibitors from a library of ubiquitinated compounds to target and inhibit key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This contributes to understanding the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention discovers that NEDD8 activator enzyme (NAE) inhibitors or their hydrochlorides possess the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator enzyme inhibitors or their hydrochlorides in the preparation of drugs for treating Japanese encephalitis, offering new targets and therapeutic strategies for the prevention and treatment of JEV.

The invention provides a traditional Chinese medicine composition with functions of softening hardness and dredging collaterals as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition with the functions of softening hardness and dredging collaterals is prepared from the following raw material medicines in parts by weight: 20-40 parts of turtle shells, 20-40 parts of radix paeoniae alba, 14-22 parts of sedum sarmentosum, 9-21 parts of teasel roots, 9-21 parts of rhizoma acori graminei, 9-21 parts of astragalus membranaceus, 14-22 parts of ligusticum wallichii and 3-15g of honey-fried licorice roots. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition adopts a treatment method of softening hardness to dissipate stagnation, dredging collaterals and relieving spasm, and can improve clinical symptoms such as cognitive impairment related to small cerebral vasculopathy of a patient, and / or anxiety and depression, and / or sleep disorder and the like. In-vitro experiments prove that the traditional Chinese medicine composition has a protection effect on human brain microvascular endothelial cell injury caused by hypoxia and reoxygenation, and can promote cell proliferation and inhibit cell apoptosis. Therefore, the traditional Chinese medicine composition can be applied to prevention and / or treatment of clinical symptoms related to small cerebral vasculopathy under the pathological mechanism of pulse stagnation and collateral arthralgia.

The present invention provides the use of NAMPT inhibitors in the manufacture of medicaments for preventing and / or treating pigmented villonodular synovitis (PVNS), and belongs to the field of medicine. In the present invention, based on the PVNS-PDX mouse model, it is found that NAMPT inhibitor FK866 exhibits significant therapeutic effects on PVNS, such as improving clinical symptoms related to the disease and inhibiting the proliferation of PVNS grafts. It is discovered that FK866 can target the NAMPT-ITGA5-JUND signaling axis, alleviate endothelial cell damage and vascular permeability, reduce synovial inflammation, decrease the volume of synovial tumor grafts, mitigate hemorrhagic lesions of PVNS, and hinder tumor progression. Therefore, NAMPT inhibitors have broad application prospects in the manufacture of medicaments for preventing and / or treating PVNS.

The invention discloses probiotic fermented litchi juice as well as a preparation method and application thereof, and relates to the technical field of probiotic fermentation. The probiotic fermented litchi juice disclosed by the invention is prepared by taking fresh litchis as a raw material and fermenting the fresh litchis by using lactobacillus mucilaginosus NCU326. The invention also provides application of the probiotic fermented litchi juice in preparation of drugs for preventing and / or improving nerve injury. The probiotic fermented litchi juice disclosed by the invention is excellent in flavor, coordinated in nutrition, unique in fermentation flavor, soft in sourness and pleasant in fragrance (a lot of olefinic terpenoids and aldehyde compounds are degraded, and the contents of alcohol, ketone, ether and acid compounds are obviously increased), and the litchi beverage fermented by NCU326 is rich in nutrients, rich in nutrients, rich in nutrients, rich in nutrients, rich in nutrients, rich in nutrients, and rich in nutrition. The survival rate of human neuroblastoma SH-SY5Y cells damaged by 1-methyl-4-phenylpyridine ions (MPP +) can be remarkably increased, and the compound has certain potential in the aspect of improving nerve injury, so that the compound can be used for preparing the medicine for preventing and / or improving nerve injury.

The present application relates to the technical field of aluminum electrolysis, and provides an aluminum electrolysis cell damage inversion method based on a machine learning algorithm, comprising the following steps: obtaining current data of an aluminum electrolysis cell through a fiber-optic current sensor, and obtaining temperature data of the aluminum electrolysis cell; performing discharge area division according to a discharger of the aluminum electrolysis cell; performing area division on the current data and the temperature data, and performing feature extraction on the current data and the temperature data; establishing a physical information forward model based on a neural network, and associating and mapping a damage state vector with current feature data and temperature feature data through the physical information forward model; constructing a cathode joint loss function and an anode joint loss function; respectively performing iterative solution on the cathode joint loss function and the anode joint loss function through an optimization algorithm, outputting an optimal damage state vector, and generating a damage space distribution result of the electrolysis cell. The present application can realize online inversion and spatial distribution visualization of anode and cathode damage states.

The invention discloses an electrical impedance-based high-pressure injector intravenous injection leakage detection alarm device, which comprises a measuring electrode band, a high-pressure injector and a detection alarm device, and is characterized in that the measuring electrode band comprises a flexible ring band, a measuring electrode and a data line, and the detection alarm device is integrated with a power supply module, a data processing module and an alarm module. The device has the beneficial effects that the device is small in cell damage, low in price, high in usability, safe, reliable and small in size, and can be integrated in a high-pressure injector to be used in linkage with the high-pressure injector; high-pressure injection liquid leakage electrical impedance data and normal data are learned in advance through a trained improved support vector regression model prediction algorithm model, and an alarm threshold point is predicted, so that the accuracy of an alarm threshold can be effectively improved, injection liquid leakage of a high-pressure injector can be well detected, an alarm can be automatically given, and injection operation can be stopped. Various complications and sequelae caused by liquid leakage can be well prevented, and double guarantees are provided for patients and hospitals.

The application discloses a method for separating and culturing primary vascular smooth muscle cells from human abdominal aortic wall, and relates to the technical field of human cell culture. The method comprises the following steps: obtaining a collagenase A solution; adding the collagenase A solution to a treated human abdominal aortic aneurysm wall tissue sample and then cutting the sample; transferring the cut human abdominal aortic aneurysm wall tissue sample to a 37-degree cell culture box for culture; centrifuging a cell suspension obtained after termination of digestion; discarding supernatant, resuspending cell precipitate, and repeating centrifugation for three times; resuspending the cell precipitate again, uniformly transferring the cell precipitate to a T25 culture bottle after blowing, and placing the cell precipitate in a 37-degree cell culture box for culture; when a wave peak and wave trough state appears, the cell precipitate is digested and subcultured by using 0.25% trypsin, and then the cell precipitate is transferred to a new T25 culture bottle; and the cell precipitate is subcultured normally to the P3 generation and then stored in liquid nitrogen, so that the cell damage is prevented and the activity and proliferation capacity of the cell are maintained.